Target- |
MechanismCell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismCell replacements |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismStem cell replacements |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) Injection in Patients With Critical Limb Ischemia
The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.
Phase I Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) Injection in Patients With Acute Ischemic Stroke
This is a single center, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.
A Clinical Study of Intracerebral Transplantation of Human Peripheral Blood Derived Induced Neural Stem Cells for Cerebral Hemorrhagic Stroke
This is a single centre、single arm、open-label,to investigate the safety and efficacy of induction of neural stem cells transplantation in the brain
100 Clinical Results associated with Allife Medical Science and Technology Co., Ltd.
0 Patents (Medical) associated with Allife Medical Science and Technology Co., Ltd.
100 Deals associated with Allife Medical Science and Technology Co., Ltd.
100 Translational Medicine associated with Allife Medical Science and Technology Co., Ltd.